Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trans-sodium crocetinate - Diffusion Pharmaceuticals

Drug Profile

Trans-sodium crocetinate - Diffusion Pharmaceuticals

Alternative Names: Crocetin sodium salt; Sodium crocetinate; Trans sodium crocetinate; Transcrocetinate sodium; TSC; TSC-cpd

Latest Information Update: 23 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Office of Naval Research; University of Virginia
  • Developer Diffusion Pharmaceuticals
  • Class Antineoplastics; Carotenoids; Neuroprotectants; Radiation-sensitising agents; Small molecules; Vascular disorder therapies
  • Mechanism of Action Oxygen compound modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain metastases; Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II Stroke
  • Preclinical Brain metastases; Pancreatic cancer
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 22 Aug 2019 Phase-II clinical trials in Stroke in USA (IV) (NCT03763929)
  • 11 Feb 2019 Diffusion Pharmaceuticals, in collaboration with the University of California Los Angeles and the University of Virginia, plans a phase II PHAST-TSC (Pre-Hospital Ambulance Stroke Trial - TSC) trial for Stroke in USA in the second quarter of 2019
  • 17 Dec 2018 Diffusion Pharmaceuticals has patent protection for the use of trans sodium crocetinate in conjunction with tissue plasminogen activator for the treatment of stroke in the US, Japan, and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top